DMAA
Drugs Made In America Acquisition Corp. Ordinary SharesKey Statistics
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company dedicated to revolutionizing the U.S. pharmaceutical sector through strategic partnerships with innovative healthcare firms. Focused on bolstering domestic drug production and mitigating supply chain risks, DMAA aims to enhance the accessibility and affordability of medications for American consumers. By harnessing advanced technologies and championing local manufacturing efforts, DMAA is poised to significantly influence the landscape of pharmaceutical access in the United States.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.22 |
| Price-to-Book | 1.11 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 18.80% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $24.28M |
| Float | $27.90M |
| % Insiders | 23.57% |
| % Institutions | 97.23% |
Historical Volatility
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DMAA and any ticker you trade — then tracks every position and per-strategy win rate.